Valence8 Us LP Celldex Therapeutics, Inc. Transaction History
Valence8 Us LP
- $241 Billion
- Q3 2024
A detailed history of Valence8 Us LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Valence8 Us LP holds 6,500 shares of CLDX stock, worth $166,725. This represents 0.09% of its overall portfolio holdings.
Number of Shares
6,500Holding current value
$166,725% of portfolio
0.09%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CLDX
# of Institutions
207Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$237 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$120 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$99.3 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$88.7 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$85.5 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.2B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...